2023 World Conference on Lung Cancer (Posters)-EP11.03. The Efficacy of Immunotherapy and Chemoimmunotherapy in STK11, KEAP1 & KRAS Gene Mutations in Advanced Non-small Cell Lung Cancer (NSCLC)

EP11.03. The Efficacy of Immunotherapy and Chemoimmunotherapy in STK11, KEAP1 & KRAS Gene Mutations in Advanced Non-small Cell Lung Cancer (NSCLC) - PDF(Slides)

Back to course

Pdf Summary

A meta-analysis of studies on immunotherapy in patients with advanced non-small cell lung cancer (NSCLC) harboring specific mutations, including KRAS, serine/threonine kinase11 (STK11), and kelch-like ECH-associated protein 1 (KEAP1), was conducted. The analysis aimed to assess the survival outcomes of immunotherapy alone or in combination with chemotherapy compared to chemotherapy alone in these patients.<br /><br />The data from nine selected studies were analyzed, and overall survival (OS) and progression-free survival (PFS) hazard ratios were extracted. The results showed that immunotherapy had a significant benefit in terms of progression-free survival compared to chemotherapy for patients with mutated KRAS. However, in patients with STK11 or KEAP1 mutations, there was no significant difference in progression-free survival between the two treatment arms.<br /><br />In terms of overall survival, patients without mutations in STK11, KEAP1, or KRAS who received immunotherapy had a lower risk of death compared to those treated with chemotherapy alone. For patients with mutated KRAS, immunotherapy had a more pronounced effect in reducing the hazard of death.<br /><br />The analysis also found that the presence of KRAS mutation was associated with a statistically significant benefit for immunotherapy compared to chemotherapy in terms of progression-free survival, while the presence of STK11 or KEAP1 mutation did not show a significant difference between the two treatment arms.<br /><br />It is important to note that the analysis was limited by the small sample size, and further prospective trials are needed to explore the effects of different KRAS mutations and other factors such as loss of heterozygosity and SMARC4A/BRG1 expression in relation to STK11 or KEAP1 mutation.<br /><br />Overall, the meta-analysis suggests that immunotherapy, particularly in patients with mutated KRAS, may offer improved survival outcomes in advanced NSCLC.

Asset Subtitle

Tony Cheung

Meta Tag

Speaker Tony Cheung

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

meta-analysis

immunotherapy

non-small cell lung cancer

NSCLC

KRAS mutation

STK11 mutation

KEAP1 mutation

chemotherapy

progression-free survival

overall survival